Purple Biotech (STU:1YI0) Other Financing: €2.95 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1YI0 Purple Biotech Ltd STU:1YI0
10 GF Score
Price €63.20
! 2 Warning Signs
View Full Analysis

What is Purple Biotech Other Financing?

Purple Biotech STU:1YI0 10 Other Financing is €2.95 Mil as of Mar. 2026. GuruFocus rates STU:1YI0 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Purple Biotech's Other Financing for the three months ended in Mar. 2026 was €-0.00 Mil.

Purple Biotech's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €2.95 Mil.

Purple Biotech Other Financing Historical Data

* Premium members only.

The historical data trend for Purple Biotech's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech Other Financing Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 -0.21 3.72 1.10 2.90

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.03 2.90 0.09 -0.00
STU:1YI0
10GF Score
Purple Biotech Ltd STU:1YI0
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €2.95 Mil mean?
Purple Biotech (STU:1YI0) has a Other Financing of €2.95 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Purple Biotech and its competitors.
Is Purple Biotech's Other Financing too high?
Purple Biotech's current Other Financing is €2.95 Mil. Overall, Purple Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Other Financing compare to VRTX and REGN?
Purple Biotech's Other Financing of €2.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Purple Biotech and its competitors. Purple Biotech's current Other Financing is €2.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (STU:1YI0) has a current Other Financing of €2.95 Mil. The current Other Financing is €2.95 Mil. Purple Biotech's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Purple Biotech (STU:1YI0), the current Other Financing is €2.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:USAPPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
10GF Score

Get the complete analysis for STU:1YI0

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.20
Price